Details for Patent: 7,799,771

Summary for Patent: 7,799,771

Title:	Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Abstract:	A pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17β-estradiol-3-lower alkanoate, most preferably 17β-estradiol-3-acetate, and a pharmaceutically acceptable carrier is disclosed. Also disclosed is a method for treating a human female in need of 17β-estradiol and a contraceptive method by oral administration of the pharmaceutical dosage unit and a method of preparing a pharmaceutical composition that may be used to form the pharmaceutical dosage unit of the invention.
Inventor(s):	Oluwole T. Aloba, Tina M. deVries
Assignee:	Allergan Therapeudics LLC
Application Number:	US11/154,704
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

United States Patent 7,799,771: Scope, Claim Charts, and U.S. Patent Landscape for Oral 17β-Estradiol-3-Acetate Solid Dosage Units with ≤5% Moisture

Executive summary US 7,799,771 protects a narrow but practical formulation space: oral solid dosage units containing 17β-estradiol-3-acetate in 0.1 to 10 mg (estradiol equivalent) plus a pharmaceutically acceptable carrier, with moisture ≤5%, optionally combined with hydrolysis inhibitors (specific acids), additional steroids (including progestational), and made by granulation; dosage forms are tablet/capsule (and broader solid-unit formats like powder/lozenge/troche). The claims primarily cover formulation and physical-parameter control (moisture) rather than route-of-synthesis or device/packaging. The closest design-arounds in U.S. freedom-to-operate are products that avoid the ≤5% moisture condition, use different hydrolysis inhibitor chemistry, avoid estradiol-equivalent dosing bands, or use fundamentally different oral presentation/processing that removes reliance on the claimed granulation-to-final-moisture combination.

---

What does US 7,799,771 claim cover for oral 17β-estradiol-3-acetate solid dosage units?

Direct answer US 7,799,771 claims an oral solid dosage unit defined by (i) active identity and dose range, (ii) a carrier, and (iii) a measurable physical attribute: moisture content ≤5%. Dependent claims add optional features: hydrolysis inhibitors selected from specified carboxylic acids, additional steroids with progestational activity, and preparation by granulation. Claim coverage includes common solid formats including tablets and capsules.

Claim 1: Core coverage (active + dose + moisture threshold + carrier)

Claim 1 elements

1. Oral solid dosage unit for a human female
2. Contains therapeutically effective amount of 17β-estradiol-3-acetate (E2-3Ac) and a pharmaceutically acceptable carrier
3. Moisture content ≤ 5% (percent moisture of the dosage unit)
4. Dose amount of E2-3Ac: 0.1 to 10 mg as estradiol equivalent

Interpretation of claim scope

• Product type limitation: “solid dosage unit for oral administration” bars liquids and non-solid presentations.
• Gender limitation: “to a human female” narrows to use for female patients but generally can be satisfied by indication or patient population in labeling; it can also be a challenge for generic “intended use” arguments.
• Moisture threshold: the key differentiator. “≤5%” is an objective numerical constraint that can be targeted in design-arounds (tight moisture control in manufacturing versus claim violation).
• Estradiol-equivalent dosing: converts actual E2-3Ac mass into estradiol-equivalent. The claim’s numeric boundaries are based on estradiol equivalent, not necessarily the same mass of E2-3Ac used by every formulation scientist. This gives some room depending on conversion assumptions, but the claim still anchors the active amount to a defined range.
• Therapeutically effective amount plus explicit dosing range: the explicit “0.1 to 10 mg as estradiol equivalent” operates as the measurable dose boundary.

Practical effect A would-be entrant must avoid infringement by changing at least one mandatory element of Claim 1: active identity (not E2-3Ac), dosage unit format (not solid for oral administration), moisture content (not ≤5%), carrier approach (still “pharmaceutically acceptable carrier” suggests broad carriers), or active amount outside the defined band.

Claim 2: Hydrolysis inhibitor embodiments (specified acids)

Claim 2 elements

• Adds “one or more pharmaceutically acceptable inhibitors of hydrolysis”
• Inhibitors selected from:
  • acetic acid
  • formic acid
  • propionic acid
  • lactic acid
  • tartaric acid

Scope implications

• The selection is closed (“selected from the group consisting of …”), which narrows compared to a broader “organic acids” concept.
• If a competitor uses a different hydrolysis inhibitor (or no inhibitor), Claim 2 should not read on that specific embodiment, though Claim 1 could still be asserted if moisture ≤5% and the dose/active conditions are met.

Claim 3-4: Additional steroids, including progestational activity

Claim 3 elements

• Further comprises “one or more additional steroids.”

Claim 4 elements

• The additional steroids have progestational activity.

Scope implications

• “Additional steroids” is broad, while Claim 4 narrows the activity.
• These claims create coverage for combination oral solid dosage units (E2-3Ac + progestins or steroidal progestational agents), so a generic or follow-on must avoid matching those combination relationships if it seeks to remove that risk.

Claim 5: Granulation preparation method (process-dependent)

Claim 5 elements

• Dosage unit “prepared by a granulation method.”

Scope implications

• This is a process limitation on preparation, which can be litigated through manufacturing documentation, batch records, and expert testimony about whether the method qualifies as “granulation.”
• A design-around could be to prepare by wet granulation, dry granulation, direct compression, or another process, but infringement hinges on claim construction of “granulation method” and evidence.

Claims 6-7: Dosage form options (tablets/capsules and other solid formats)

Claim 6 elements

• Dosage unit is one of: tablet, capsule, powder, lozenge, troche

Claim 7 elements

• specifically tablet or capsule

Scope implications

• Claim 7 is narrower and easier to map to manufacturing and commercialization.
• Claim 6 expands to additional solid unit presentations beyond immediate conventional unit operations.

---

How do the claim limitations control infringement risk versus common formulation changes?

Moisture ≤5%: the highest-leverage infringement hook

• Key risk factor: If a competitor’s final product has moisture content at or below 5%, the formulation can still fall within Claim 1 even if the competitor changes excipients, manufacturing method (unless only process limitations are asserted), or hydrolysis inhibitor selection.
• Evidentiary pathway: moisture content is measurable, so the patent can be enforced with testing and process characterization.

Hydrolysis inhibitor selection: narrow group in Claim 2

• Using only one of the specified acids could satisfy Claim 2 if the rest of Claim 1 also reads.
• Using other inhibitors could avoid Claim 2 while leaving Claim 1 exposure unchanged.

Additional steroids/progestational activity: combination-specific exposure

• Combination products increase overlap with Claim 3/4.
• Monotherapy products avoid those dependent claims if they do not add progestational steroid(s), while Claim 1 may still be asserted.

Granulation method: potential design-around for process

• If a competitor can show it did not use a “granulation method” as construed, Claim 5 exposure can be reduced.
• But Claim 1 is not process-limited in the excerpt; avoidance of Claim 5 alone does not eliminate Claim 1 exposure.

Dosage unit form: tablet/capsule as the most commercially likely overlap

• If competitor makes tablets or capsules with E2-3Ac at the claimed dose range and moisture condition, the infringement mapping becomes straightforward for Claim 1 and Claim 7.

---

How strong is the patent estate for US 7,799,771 on E2-3Ac oral solids?

Executive answer Within the provided claim set, strength is concentrated on a quantified formulation property (moisture ≤5%), explicit active/dosing boundaries, and limited dependent features (specific acid inhibitors; progestational steroid combinations; granulation). The patent’s enforceability and practical deterrence will depend on whether market entrants must operate within the same stability envelope to maintain E2-3Ac integrity in oral solids.

Claim strength drivers

• Objective numerical limit: “percent moisture ≤5%” supports clearer validity and infringement comparisons than purely qualitative formulation features.
• Closed inhibitor list in Claim 2: narrows claim breadth, improving defensibility against “prior art teaches acids generally” arguments, but also limits coverage against alternatives.
• Process limitation in Claim 5: increases specificity but may be easier to challenge if competitors use different manufacturing routes.

Claim vulnerability drivers

• The moisture limit may be attacked if prior art teaches stable solid E2-3Ac formulations achieving ≤5% moisture or if moisture levels are inherent/obvious in standard solid manufacturing.
• The dose range and active identity may overlap with earlier disclosures if E2-3Ac oral solids and relevant dosing are already known.

---

What patents protect adjacent formulation concepts for oral 17β-estradiol-3-acetate?

Executive answer The most common adjacent protection clusters around:

1. E2-3Ac oral solid formulations (stability and degradation control)
2. Moisture or water activity control
3. Hydrolysis inhibition using specific acid classes or other stabilizers
4. Particle engineering (micronization, crystallinity, amorphous stabilization)
5. Combination regimens with progestins
6. Manufacturing process claims (granulation vs direct compression; spray drying; extrusion/spheronization where relevant)

Direct connection to US 7,799,771

• Claim 1 aligns with stability-through-formulation claims.
• Claim 2 aligns with stabilizer selection claims.
• Claim 5 aligns with manufacturing-process claims.
• Claim 3/4 aligns with combination steroid claims.

---

When does US 7,799,771 lose exclusivity in the U.S.?

Executive answer Cannot be determined from the claim excerpt alone. The expiration date depends on the application filing date, any priority claims, patent term adjustment, and whether it is a utility patent with standard 20-year term from earliest non-provisional filing.

---

What is the Orange Book status of US 7,799,771 and what products might be covered?

Executive answer Cannot be determined from the claim excerpt alone. Orange Book status requires linking the patent to an FDA application number and listed drug product.

---

How do Paragraph IV challenges affect the commercial risk for E2-3Ac oral solids?

Executive answer Cannot be determined from the claim excerpt alone. Paragraph IV risk requires knowing whether the patent is listed in the Orange Book for a relevant reference listed drug and whether any ANDA applicants filed certifications tied to this patent.

---

What generic entry risks exist for moisture-controlled E2-3Ac oral tablets or capsules?

Executive answer The largest generic entry risk sits with generic products attempting to copy:

• E2-3Ac active,
• oral solid dosage unit presentation,
• dose range in estradiol-equivalent terms,
• and moisture content ≤5%.

A generic can reduce risk by designing around the moisture threshold or altering essential claim elements, but the feasibility depends on whether moisture content can be moved above 5% without causing unacceptable hydrolysis or quality issues.

---

How does US 7,799,771 compare with likely competing formulation strategies?

Executive answer Relative to broader “E2-3Ac solid formulation” patents, US 7,799,771 is tighter because it mandates ≤5% moisture. Compared with patents covering broad excipient classes or broad stabilizer types, it is narrower in stabilizer identity (Claim 2) and broader in carrier acceptance (Claim 1). The practical competitive differentiator for entrants is whether they can satisfy E2-3Ac stability while avoiding the specific moisture band and, if needed, avoiding granulation.

---

Key claim-to-design-around mapping (infringement avoidance levers)

Claim feature	Competitor design-around lever	Likely litigation focus
Oral solid dosage unit	Switch to non-solid or non-oral	Claim construction of “solid dosage unit for oral administration”
17β-estradiol-3-acetate	Use different estradiol prodrug/ester or different active	Active identity testing
Dose 0.1 to 10 mg as estradiol equivalent	Re-dose outside band	Dose calculation assumptions
Moisture ≤5%	Set moisture above 5% or show it is not reliably ≤5%	Moisture testing, batch variability, specs
Hydrolysis inhibitor acids (Claim 2)	Use different stabilizers or none	Whether the chosen inhibitor matches listed group
Additional steroids with progestational activity (Claim 4)	Avoid progestational steroid combinations	Formulation composition
Granulation method (Claim 5)	Use non-granulation manufacturing route	Whether method qualifies as “granulation”
Tablet/capsule (Claims 6-7)	Use other listed solid formats (or non-covered forms)	Product type mapping

---

Key Takeaways

• US 7,799,771’s claim set is centered on an oral solid formulation of 17β-estradiol-3-acetate with moisture ≤5% and 0.1 to 10 mg (estradiol equivalent) per unit dose.
• Dependent claims add targeted coverage for specific hydrolysis inhibitor acids, progestational steroid combinations, and granulation processing, plus broad solid unit forms and narrower tablet/capsule coverage.
• The most potent infringement risk lever for entrants is meeting the moisture constraint alongside the active identity and dosing band.
• Design-arounds most plausibly focus on moisture content, stabilizer selection (for Claim 2), combination composition (for Claims 3/4), and manufacturing route (for Claim 5).
• Exclusivity timelines, Orange Book listings, Paragraph IV challenges, and actual enforcement posture cannot be concluded from the claim excerpt alone.

---

FAQs

1. Does US 7,799,771 cover direct compression tablets if they are not made by granulation?
2. If a competitor’s E2-3Ac capsule has moisture above 5%, does it avoid all claims or only Claim 1?
3. Can a generic avoid Claim 2 by using a hydrolysis inhibitor that is not acetic, formic, propionic, lactic, or tartaric acid while still matching moisture and dose limits?
4. Do Claims 3-4 require a specific named progestin, or is any steroidal progestational activity sufficient?
5. How do moisture testing methods and batch variability affect whether a product meets the ≤5% threshold in practice?

---

References (APA)

1. United States Patent No. 7,799,771.

Drugs Protected by US Patent 7,799,771

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,799,771

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2002359758
Canada	2470703
China	1273141
China	1564689
European Patent Office	1461043
Israel	160797